Stuart E. Builder
Stuart E. Builder publishes mostly in Molecular Biology, Biotechnology and Spectroscopy, on topics such as Protein purification and stability, Viral Infectious Diseases and Gene Expression in Insects and Monoclonal and Polyclonal Antibodies Research.
- World rank
- #1,165,942 of 7,710,434 ranked researchers
- Rank in United States
- #374,993 of 1,627,098
- Works
- 33
- Citations
- 1.4k
- Citations per work
- 43.5
What does Stuart E. Builder research?
Stuart E. Builder's work is mostly in Biochemistry, Genetics and Molecular Biology (48%), Medicine (9%), Chemistry (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences1647.5%
- Everything else1133.7%
- Physical Sciences310.0%
- Chemistry25.0%
- Engineering25.0%
- Health Sciences38.8%
- Medicine38.8%
- 1Molecular Biology40% of their works
- 2Biotechnology8% of their works
- 3Spectroscopy5% of their works
- 4Radiology, Nuclear Medicine and Imaging5% of their works
- 5Biomedical Engineering5% of their works
- 6Endocrinology, Diabetes and Metabolism4% of their works
Research topics
- Protein purification and stability
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Transgenic Plants and Applications
- Growth Hormone and Insulin-like Growth Factors
- Microbial Inactivation Methods
- Protease and Inhibitor Mechanisms
- Glycosylation and Glycoproteins Research
Which keywords describe Stuart E. Builder's research?
The keywords of their largest research topics: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Biopharmaceuticals, Recombinant Proteins, Protein Aggregation, Stability and Mammalian Cells.
- Tissue Inhibitors of Metalloproteinases
- Irreversible Electroporation
- Glycans
- Vaccine Antigens
- Insulin-like Growth Factors
- Fc Receptors
- Cancer
- Mammalian Cells
- Protein Aggregation
- Biopharmaceuticals
- Monoclonal Antibodies
- Glycosylation
- Therapeutic Antibodies
- Recombinant Proteins
- Stability
- Recombinant Protein
- Antibody Engineering
- IGF-1
- Plant Molecular Farming
- Electroporation
- Immune System
- Matrix Metalloproteinases
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Glycosylation173 topics
- Monoclonal Antibodies172 topics
- Therapeutic Antibodies172 topics
- Biopharmaceuticals162 topics
- Recombinant Proteins162 topics
- Protein Aggregation131 topic
- Stability131 topic
- Mammalian Cells111 topic
- Recombinant Protein111 topic
- Cancer52 topics
- Antibody Engineering41 topic
- Fc Receptors41 topic
- IGF-131 topic
- Insulin-like Growth Factors31 topic
- Plant Molecular Farming31 topic
- Vaccine Antigens31 topic
- Electroporation21 topic
- Glycans21 topic
- Immune System21 topic
- Irreversible Electroporation21 topic
- Matrix Metalloproteinases21 topic
- Tissue Inhibitors of Metalloproteinases21 topic
Where does Stuart E. Builder work?
Stuart E. Builder's main affiliation in the publication record is New Frontier, United States.
How many publications and citations does Stuart E. Builder have?
OpenAlex counts 33 works and 1,436 citations for Stuart E. Builder, an h-index of 18, ranking #1,165,942 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Stuart E. Builder. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.